Stock listing
A1W50M Stock Price, News, Filings & Events — Fate Therapeutics, Inc.
Selected listing: A1W50M · LS · EUR · DE
This page tracks Fate Therapeutics, Inc.'s A1W50M:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A1W50M:LS. A1W50M:LS is the stock-level entry point for investors researching Fate Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fate Therapeutics, Inc. is a public biotechnology company based in the United States, focused on developing cellular immunotherapies for cancer and immune disorders. The company is traded under the ticker symbol FATE and has a market capitalization of approximately $280.9 million. Fate Therapeutics aims to advance its innovative therapies through research and development in the field of regenerative medicine.
- Ticker
- A1W50M:LS
- Asset type
- Stock
- Market cap
- $276.8M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Fate Therapeutics, Inc. A1W50M:LS stock context
This page tracks Fate Therapeutics, Inc.'s A1W50M:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A1W50M:LS. A1W50M:LS is the stock-level entry point for investors researching Fate Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fate Therapeutics, Inc. is a public biotechnology company based in the United States, focused on developing cellular immunotherapies for cancer and immune disorders. The company is traded under the ticker symbol FATE and has a market capitalization of approximately $280.9 million. Fate Therapeutics aims to advance its innovative therapies through research and development in the field of regenerative medicine.
Latest news from Fate Therapeutics, Inc.
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 ...
September 10, 2026
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 ...
September 9, 2026
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
September 3, 2026
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
August 14, 2026
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 13, 2026
Fate Therapeutics, Inc. earnings calls
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call
May 9, 2024 · Replay with transcript and chapters
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call
February 26, 2024 · Replay with transcript and chapters
Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call
November 8, 2023 · Replay with transcript and chapters
Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call
August 8, 2023 · Replay with transcript and chapters
Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call
May 3, 2023 · Replay with transcript and chapters
Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call
February 28, 2023 · Replay with transcript and chapters
Research Fate Therapeutics, Inc.
Fate Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for A1W50M:LS.
Fate Therapeutics, Inc. company profile
View the public company page for Fate Therapeutics, Inc. on 6ix.
Fate Therapeutics, Inc. news
Read company news and market updates connected to Fate Therapeutics, Inc..
Fate Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Fate Therapeutics, Inc..
Alternate listings
FATE:NASDAQ
US · USD
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
F6T:GETTEX
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
FATE:BOATS
US · USD
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
A1W50M:LSX
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
F6T:FWB
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
F6T:SWB
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
F6T:DUS
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
F6T:MUN
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.
F6T:TRADEGATE
DE · EUR
Alternate listing for Fate Therapeutics, Inc.; the primary context on this page is A1W50M:LS.